FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4307441514> ?p ?o ?g. }

• W4307441514 abstract "Back to table of contents Previous article Next article Med CheckFull AccessMed Check: Lecanemab; ANEB-001; Azstarys; and MoreTerri D’ArrigoTerri D’ArrigoSearch for more papers by this authorPublished Online:27 Oct 2022https://doi.org/10.1176/appi.pn.2022.11.11.2Lecanemab May Slow Decline in Alzheimer’sLecanemab, an investigational anti-amyloid beta protofibril antibody, may slow cognitive decline in Alzheimer’s disease, Biogen Inc. and Esai Co. Ltd. announced in September. Lecanemab is being developed for the treatment of mild cognitive impairment from Alzheimer’s disease and mild or early Alzheimer’s disease with confirmed presence of amyloid pathology in the brain.In the phase 3 Clarity AD trial, 1,795 patients with early Alzheimer’s disease were randomized to receive either placebo or biweekly doses of 10 mg of lecanemab per kilogram of body weight. The primary endpoint was reduced clinical decline, as measured by the Clinical Dementia Rating-Sum of Boxes (CDR-SB). At the end of 18 months, CDR-SB scores had declined by 27% less in patients who received lecanemab compared with those who received placebo. The CDR-SB scores were a mean 0.45 points lower for those who received lecanemab compared with those who received placebo.Last year the Food and Drug Administration (FDA) granted Breakthrough Therapy designation to lecanemab based on the results of a phase 2b clinical trial, which examined the impact of treatment with lecanemab on reducing amyloid beta and clinical decline, as measured by changes on the Alzheimer’s Disease Composite Score (ADCOMS). Breakthrough Therapy designation expedites the development and review of drugs for serious conditions.In the trial, 856 patients who had mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease dementia were randomized to receive 2.5 mg/kg, 5 mg/kg, or 10 mg/kg of lecanemab once every two weeks; 5 mg/kg or 10 mg/kg of lecanemab once every four weeks; or placebo for 18 months. Patients who took 10 mg/kg biweekly lecanemab had a 76% probability of achieving 25% less decline on ADCOMS compared with those who took placebo. ANEB-001 May Reverse Cannabinoid IntoxicationA phase 2 trial of the investigational cannabinoid receptor agonist ANEB-001 suggests that the medication may reverse cannabinoid intoxication, Anebulo Pharmaceuticals Inc. announced in September.The trial involved approximately 60 participants, who were given 21 mg of delta-9-tetrahydrocannabinol (THC). They were then given 10 mg of ANEB-001, 30 mg of ANEB-001, or placebo.Those who received placebo reported a substantial increase in feeling high and body sway, decreased alertness, and a slightly increased heart rate from baseline. Participants who received either 10 mg or 30 mg of ANEB-001 experienced significant reductions in the visual analog scale (VAS) score for feeling high, improvement in the VAS alertness scale, and a reduction in THC-induced body sway compared with those who received placebo. Azstarys May Improve Sleep for Children with ADHDAzstarys (serdexmethylphenidate and dexmethylphenidate) may help improve sleep in children with attention-deficit/hyperactivity disorder (ADHD), Corium Inc. announced in September. Azstarys is approved for the treatment of ADHD in patients aged six years and older.In a one-year open-label study, 238 children with ADHD aged six to 12 years received Aztarys for one year. After one month of treatment with Azstarys, the children’s total average sleep disturbance score on the Children’s Sleep Habits Questionnaire (CSHQ) decreased significantly from a mean of 53.4 points to 50.5 points. Furthermore their total mean CSHQ scores remained between 48.9 to 50.1 points for up to 12 months, indicating that the improvements in their sleep were sustained.The results of the study were presented in a poster at the Psych Congress 2022 in New Orleans. FDA Reviews Two-Month Aripiprazole Injection for SchizophreniaIn September, Otsuka America Pharmaceutical Inc. and H. Lundbeck A/S announced that the FDA has accepted for review a New Drug Application (NDA) for aripiprazole two-month, long-acting injectable for the treatment of schizophrenia in adults and for maintenance monotherapy of bipolar I disorder in adults. The NDA is for a formulation designed to be administered via intramuscular injection in the gluteal muscle.The NDA is based on data from a clinical trial involving 266 patients who were randomized to receive either four 920 mg injections of aripiprazole two-month long-acting injectable or eight 400 mg injections of aripiprazole one-month depot. Plasma concentrations of aripiprazole were similar between both groups of patients, and the two-month injectable was well-tolerated and showed no safety concerns compared with the once-monthly injectable. ■ ISSUES NewArchived" @default.
• W4307441514 created "2022-11-01" @default.
• W4307441514 creator A5056763663 @default.
• W4307441514 date "2022-11-01" @default.
• W4307441514 modified "2023-09-26" @default.
• W4307441514 title "Med Check: Lecanemab; ANEB-001; Azstarys; and More" @default.
• W4307441514 doi "https://doi.org/10.1176/appi.pn.2022.11.11.2" @default.
• W4307441514 hasPublicationYear "2022" @default.
• W4307441514 type Work @default.
• W4307441514 citedByCount "0" @default.
• W4307441514 crossrefType "journal-article" @default.
• W4307441514 hasAuthorship W4307441514A5056763663 @default.
• W4307441514 hasConcept C126322002 @default.
• W4307441514 hasConcept C142724271 @default.
• W4307441514 hasConcept C203092338 @default.
• W4307441514 hasConcept C204787440 @default.
• W4307441514 hasConcept C27081682 @default.
• W4307441514 hasConcept C2779134260 @default.
• W4307441514 hasConcept C2779483572 @default.
• W4307441514 hasConcept C2780906993 @default.
• W4307441514 hasConcept C2984863031 @default.
• W4307441514 hasConcept C502032728 @default.
• W4307441514 hasConcept C535046627 @default.
• W4307441514 hasConcept C71924100 @default.
• W4307441514 hasConceptScore W4307441514C126322002 @default.
• W4307441514 hasConceptScore W4307441514C142724271 @default.
• W4307441514 hasConceptScore W4307441514C203092338 @default.
• W4307441514 hasConceptScore W4307441514C204787440 @default.
• W4307441514 hasConceptScore W4307441514C27081682 @default.
• W4307441514 hasConceptScore W4307441514C2779134260 @default.
• W4307441514 hasConceptScore W4307441514C2779483572 @default.
• W4307441514 hasConceptScore W4307441514C2780906993 @default.
• W4307441514 hasConceptScore W4307441514C2984863031 @default.
• W4307441514 hasConceptScore W4307441514C502032728 @default.
• W4307441514 hasConceptScore W4307441514C535046627 @default.
• W4307441514 hasConceptScore W4307441514C71924100 @default.
• W4307441514 hasIssue "11" @default.
• W4307441514 hasLocation W43074415141 @default.
• W4307441514 hasOpenAccess W4307441514 @default.
• W4307441514 hasPrimaryLocation W43074415141 @default.
• W4307441514 hasRelatedWork W167815567 @default.
• W4307441514 hasRelatedWork W2061194377 @default.
• W4307441514 hasRelatedWork W2114140099 @default.
• W4307441514 hasRelatedWork W2160475077 @default.
• W4307441514 hasRelatedWork W2279154019 @default.
• W4307441514 hasRelatedWork W2472353213 @default.
• W4307441514 hasRelatedWork W2981304007 @default.
• W4307441514 hasRelatedWork W313460363 @default.
• W4307441514 hasRelatedWork W3173229286 @default.
• W4307441514 hasRelatedWork W4306173869 @default.
• W4307441514 hasVolume "57" @default.
• W4307441514 isParatext "false" @default.
• W4307441514 isRetracted "false" @default.
• W4307441514 workType "article" @default.